583840-04-4 Usage
Uses
Used in Anticancer Applications:
Sorafenib Impurity 13 is used as an anti-proliferative agent for its ability to inhibit the growth of human breast cancer cells. It interferes with the cell division process, thereby preventing the uncontrolled proliferation of cancer cells and potentially contributing to the treatment of breast cancer.
Used in Pharmaceutical Research:
Sorafenib Impurity 13 serves as an important compound in the field of pharmaceutical research, where it can be utilized to study the mechanisms of action, metabolism, and potential side effects of the parent drug, Sorafenib. This knowledge can be applied to improve the drug's efficacy and safety profile, ultimately benefiting patients undergoing cancer treatment.
Used in Drug Development:
In the drug development industry, Sorafenib Impurity 13 can be employed as a reference material for the synthesis and optimization of new anti-cancer agents. By understanding the structure-activity relationship of this impurity, researchers can design and develop novel drugs with improved pharmacological properties and reduced side effects.
Used in Quality Control:
Sorafenib Impurity 13 is used as a reference standard in the quality control of Sorafenib drug products. It helps ensure the purity, potency, and consistency of the final drug formulation, which is crucial for maintaining the safety and effectiveness of the medication for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 583840-04-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,3,8,4 and 0 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 583840-04:
(8*5)+(7*8)+(6*3)+(5*8)+(4*4)+(3*0)+(2*0)+(1*4)=174
174 % 10 = 4
So 583840-04-4 is a valid CAS Registry Number.
583840-04-4Relevant academic research and scientific papers
Aryl ureas as kinase inhibitors
-
Page/Page column 21; 23, (2015/11/30)
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VE
Aryl ureas as kinase inhibitors
-
, (2008/06/13)
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
-
, (2008/06/13)
This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
